What do systematic reviews say?

Summary of Findings Table ‐ Antithrombin concentrates vs no antithrombin concentrates

It is very uncertain whether summary of Findings Table ‐ Antithrombin concentrates changes venous thromboembolism‐related mortality ‐ Intention‐to‐treat analysis compared with no antithrombin concentrates (very low certainty).

• Prophylaxis of thromboembolism during therapy with asparaginase in adults with acute lymphoblastic leukaemia 2020 · Cochrane Headline outcomes only
  RR 0.1 [0.01, 1.94]
  1 study · 40 participants
  Very low

Summary of Findings Table ‐ Antithrombin concentrates vs no antithrombin concentrates

The review found no eligible studies for this question.

• Prophylaxis of thromboembolism during therapy with asparaginase in adults with acute lymphoblastic leukaemia 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of Findings Table ‐ Antithrombin concentrates vs no antithrombin concentrates

• Prophylaxis of thromboembolism during therapy with asparaginase in adults with acute lymphoblastic leukaemia 2020 · Cochrane Headline outcomes only
  no estimate extracted
  0 studies · 0 participants
  GRADE not reported

Summary of Findings Table ‐ Antithrombin concentrates vs no antithrombin concentrates

The review found no eligible studies for this question.

• Prophylaxis of thromboembolism during therapy with asparaginase in adults with acute lymphoblastic leukaemia 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of Findings Table ‐ Enoxaparin vs no enoxaparin

The review found no eligible studies for this question.

• Prophylaxis of thromboembolism during therapy with asparaginase in adults with acute lymphoblastic leukaemia 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of Findings Table ‐ Enoxaparin vs no enoxaparin

• Prophylaxis of thromboembolism during therapy with asparaginase in adults with acute lymphoblastic leukaemia 2020 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 224 participants
  GRADE not reported

Fluoride gel (topically applied; operator- or self-applied; any fluoride agent/concentration; frequency at least once a year) vs High-content fluoride toothpaste (1350 ppm)

• Interventions for preventing osteoradionecrosis of the jaws in adults receiving head and neck radiotherapy 2019 · Cochrane All outcomes

  14 to 36 months
  Adverse effects were an outcome of interest in the study conducting this comparison, however no mention was made of the presence or absence of any adverse events
  1 study · 220 participants
  Very low

Intervention not reported

The intervention leads to higher smoking cessation at longest (high certainty).

• Additional behavioural support as an adjunct to pharmacotherapy for smoking cessation 2019 · Cochrane Headline outcomes only
  RR 1.15 [1.08, 1.22]
  65 studies · 23331 participants
  High

Taxane followed by anthracyclines vs anthracyclines followed by taxane

Taxane followed by anthracyclines showed no clear difference in overall survival ( compared with anthracyclines followed by taxane (moderate certainty).

• Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer 2019 · Cochrane Headline outcomes only
  HR 0.8 [0.6, 1.08]
  2 studies · 947 participants
  Moderate

Taxane followed by anthracyclines vs anthracyclines followed by taxane

Taxane followed by anthracyclines leads to lower adverse events: neutropenia (grade 3/4) ( compared with anthracyclines followed by taxane (high certainty).

• Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer 2019 · Cochrane Headline outcomes only
  RR 0.62 [0.4, 0.97]
  4 studies · 279 participants
  High

Taxane followed by anthracyclines vs anthracyclines followed by taxane

Taxane followed by anthracyclines showed no clear difference in adverse events: neurotoxicity (grade 3/4) ( compared with anthracyclines followed by taxane (low certainty).

• Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer 2019 · Cochrane Headline outcomes only
  RR 0.78 [0.25, 2.46]
  3 studies · 162 participants
  Low

Taxane followed by anthracyclines vs anthracyclines followed by taxane

Taxane followed by anthracyclines showed no clear difference in treatment adherence (defined as dose delay) ( compared with anthracyclines followed by taxane (moderate certainty).

• Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer 2019 · Cochrane Headline outcomes only
  RR 0.76 [0.52, 1.12]
  3 studies · 238 participants
  Moderate

Taxane followed by anthracyclines vs anthracyclines followed by taxane

• Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer 2019 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 20 participants
  Moderate

Taxane followed by anthracyclines vs anthracyclines followed by taxane

Taxane followed by anthracyclines showed no clear difference in disease‐free survival ( compared with anthracyclines followed by taxane (moderate certainty).

• Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer 2019 · Cochrane Headline outcomes only
  HR 0.84 [0.65, 1.09]
  1 study · 828 participants
  Moderate

Taxane followed by anthracyclines vs anthracyclines followed by taxane

Taxane followed by anthracyclines showed no clear difference in pathological complete response (no invasive cancer in breast or… compared with anthracyclines followed by taxane (high certainty).

• Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer 2019 · Cochrane Headline outcomes only
  RR 1.15 [0.96, 1.38]
  4 studies · 1280 participants
  High

Taxane followed by anthracyclines vs anthracyclines followed by taxane

Taxane followed by anthracyclines showed no clear difference in adverse events: neutropenia (grade 3/4) ( compared with anthracyclines followed by taxane (moderate certainty).

• Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer 2019 · Cochrane Headline outcomes only
  RR 1.25 [0.86, 1.82]
  1 study · 280 participants
  Moderate

Taxane followed by anthracyclines vs anthracyclines followed by taxane

Taxane followed by anthracyclines showed no clear difference in adverse events: neurotoxicity (grade 3/4) ( compared with anthracyclines followed by taxane (low certainty).

• Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer 2019 · Cochrane Headline outcomes only
  RR 0.95 [0.55, 1.65]
  2 studies · 1108 participants
  Low

Taxane followed by anthracyclines vs anthracyclines followed by taxane

Taxane followed by anthracyclines showed no clear difference in treatment adherence (defined as dose reduction) ( compared with anthracyclines followed by taxane (moderate certainty).

• Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer 2019 · Cochrane Headline outcomes only
  RR 0.81 [0.59, 1.11]
  1 study · 280 participants
  Moderate

Taxane followed by anthracyclines vs anthracyclines followed by taxane

The review found no eligible studies for this question.

• Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Taxane followed by anthracyclines vs anthracyclines followed by taxane

The review found no eligible studies for this question.

• Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found